07th week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160045558 | COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS - A composition including | 2016-02-18 |
20160045559 | COMPOSITIONS AND METHODS FOR MANAGING OR IMPROVING BONE DISORDERS, CARTILAGE DISORDERS, OR BOTH - The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of useful for promoting, managing or improving bone health, cartilage health or both, or for preventing or treating a bone disorder, cartilage disorder or both. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other bone and cartilage management agents, such as calcium, magnesium, zinc, boron, vitamin D, vitamin K, glucosamine and/or chondroitin compounds, non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, neuropathic pain relief agents, or the like. | 2016-02-18 |
20160045560 | WEIGHT LOSS FORMULATION - A weight loss product comprises a mixture of | 2016-02-18 |
20160045561 | Antioxidatively Active Composition and the Use Thereof - The present invention relates to an antioxidatively active composition including at least one polyphenol rich plant extract; at least one porphyrine, and at least one additional compound from the group of stilbenoids, and the use thereof. | 2016-02-18 |
20160045562 | Peptides for the Treatment of Cancer - The present invention relates to an isolated peptide for use in the treatment of cancer consisting of 12 to 50 amino acid residues comprising—at least two beta-strands, or—at least two alpha-helices or—at least one beta-strand and at least one alpha-helix, —wherein said beta-strands and/or alpha-helices are preferably separated from each other by at least one turn, wherein the peptide has a net positive charge of +7 or more; —wherein said peptide comprises at least one peptide moiety having amino acid sequence (X | 2016-02-18 |
20160045563 | MUSCLE-ATROPHY-PREVENTING AGENT - A muscle atrophy-preventing agent includes a milk-derived basic protein fraction and/or a decomposed product of the milk-derived basic protein fraction as an active ingredient. The muscle atrophy-preventing agent is remarkably effective in preventing muscle mass decline and increasing muscle mass, and thus is useful in preventing and treating various muscle diseases, such as sarcopenia and disuse muscle atrophy. | 2016-02-18 |
20160045564 | THERAPEUTIC USE OF A GROWTH FACTOR, METRNL - The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects. | 2016-02-18 |
20160045565 | METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES - The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders. | 2016-02-18 |
20160045566 | ANGIOPOIETIN-BASED INTERVENTIONS FOR TREATING CEREBRAL MALARIA - The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1. | 2016-02-18 |
20160045567 | USE OF M-CSF FOR PREVENTING OR TREATING MYELOID CYTOPENIA AND RELATED COMPLICATIONS - The invention relates to methods and compositions comprising a macrophage colony stimulating factor (M-CSF) polypeptide or an agonist of the M-CSF receptor for preventing or treating myeloid cytopenia and related complications (such as infections) in a patient in need thereof (such as a patient undergoing hematopoietic stem cell transplantation). | 2016-02-18 |
20160045568 | CITRATE FREE PHARMACEUTICAL COMPOSITIONS COMPRISING ANAKINRA - The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment. | 2016-02-18 |
20160045569 | ENDOGENOUS VACCINE FOR CANCER AND INFECTIOUS DISEASES - The present invention is directed to an endogenous vaccine targeted to a cancer or an infectious disease. | 2016-02-18 |
20160045570 | BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNB AND USES THEREOF - Methods, assays and kits for the identification, assessment and/or treatment of a subject having multiple sclerosis (MS) (e.g., a patient with relapsing-remitting multiple sclerosis (RRMS)) are disclosed. | 2016-02-18 |
20160045571 | OSTEOCALCIN AS A TREATMENT FOR COGNITIVE DISORDERS - Methods and compositions for treating or preventing cognitive disorders in mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-1B signaling pathway involving gamma-carboxylase and osteocalcin, e.g., by administration of undercarboxylated/uncarboxylated osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, cognitive loss due to neurodegeneration associated with aging, anxiety, depression, memory loss, learning difficulties, and cognitive disorders associated with food deprivation during pregnancy. | 2016-02-18 |
20160045572 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME - This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived. | 2016-02-18 |
20160045573 | NANOPARTICLES WITH EFFECTS ON ENDOTHELIAL FUNCTION AND MEMBRANE PERMEABILITY - The present invention relates to a method using fibrinogen-coated albumin spheres for treating a patient infected with a hemorrhagic virus. A suspension of protein nanoparticle containing submicron protein spheres is prepared and administered to the patient. The protein spheres are bound with fibrinogen molecules in vitro or in vivo. The fibrinogen-coated albumin spheres provide improved hemostatic function of a residual concentration of platelets of the patient resulting in decreasing mortality rate or decreasing morbidity of the patient. The fibrinogen-coated albumin spheres protect an endothelial function of an endothelial cell of a blood vessel of the patient resulting in improved permeability control across predetermined tissues in the patient, thereby counteracting an effect of the hemorrhagic virus on a wall of the blood vessel. | 2016-02-18 |
20160045574 | ANTIVIRAL PHARMACEUTICAL FOR TOPICAL ADMINISTRATION - An enzymatically-active ribonuclease is combined with a vehicle that does not unacceptably interfere with such enzymatic activity and applied externally. Advantageously, the ribonuclease is ranpirnase. The vehicle can be a liquid, a gel, an ointment, or a serum, and can also be an approved sexual lubricant. | 2016-02-18 |
20160045575 | FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION AND RELATED cDNAs, COMPOSITIONS, METHODS AND SYSTEMS - The present disclosure relates to methods, systems, and compositions to repair one or more mutations in a Factor VIII gene sequence of a subject by introducing into a cell of the subject one or more polynucleotides encoding a DNA scission enzyme (DNA-SE) and one or more repair vehicles (RVs) containing at least a cDNA-repair sequence (RS) such that insertion of the cDNA-RS through homologous recombination with the F8 gene of the subject (sF8) provides a repaired F8 gene (rF8), the repaired F8 gene (rF8) upon expression forming a functional FVIII conferring improved coagulation functionality to the FVIII protein encoded by the sF8. The present disclosure also relates to cells derived using the methods, systems and compositions described. | 2016-02-18 |
20160045576 | Enzyme Delivery Systems and Methods of Preparation and Use - This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders. | 2016-02-18 |
20160045577 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - A method of treating circadian rhythm disorders includes identifying a subject with a circadian rhythm disorder or at least one symptom of a circadian rhythm disorder and administering an effective amount of a composition comprising a botulinum toxin and a pharmaceutically acceptable carrier to said subject thereby reducing at least one symptom of a circadian rhythm disorder. | 2016-02-18 |
20160045578 | Novel Polypeptides Having Endolysin Activity and Uses Thereof - The present invention provides isolated polypeptides comprising the amino acid sequence of SEQ ID NO: 1, or a fragment, variant, derivative or fusion thereof which is capable of binding specifically to and/or lysing cells of | 2016-02-18 |
20160045579 | DIABETES TREATMENT - Methods and compositions for treating a patient who has recently developed diabetes are provided. The methods can include administering a tolerance-restoring agent to the patient and simultaneously administering intensive insulin therapy. | 2016-02-18 |
20160045580 | IDENTIFICATION OF CD8+ T CELLS THAT ARE CD161HI AND/OR IL18R(ALPHA)HI AND HAVE RAPID DRUG EFFLUX CAPACITY - This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8 | 2016-02-18 |
20160045581 | Parasitic Biological Agents for Treatment and Prevention of Graft Versus Host Disease - The invention relates to helminthic parasite preparations and their use for treatment or prevention of GVHD in a subject that has undergone a transplant. The invention also related to helminthic parasite preparations and their use for prevention of GVHD in a subject prior to a transplant. | 2016-02-18 |
20160045582 | CONJUGATE VACCINE USING TRIMMING FUNCTION OF ERAP1 - The present invention provides a compound represented by the formula (1): | 2016-02-18 |
20160045583 | Tumor Vaccine - The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, and method for stimulating an immune response to a tumor with the tumor cell so genetically modified. The invention additionally provides a method of inhibiting a tumor, including a cancer such as lung cancer, by administering an allogeneic tumor cell, for example a cancer tumor cell such as a lung cancer tumor cell, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen. | 2016-02-18 |
20160045584 | CAMPYLOBACTER VACCINE - The present application provides a vaccine composition comprising: bacteria engineered to express at least one N-glycan of | 2016-02-18 |
20160045585 | FORMULATIONS - This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material comprises a microorganism. In particular, the invention relates to compositions comprising a microorganism selected from live, killed, attenuated and inactivated microorganisms. The matrix material may also comprise a surfactant and may further comprise an adjuvant. The invention further relates to the manufacture and use of such compositions, and to other subject matter. | 2016-02-18 |
20160045586 | Toxoid, Compositions and Related Methods - The disclosure relates to generally to the field of toxin inactivation. More specifically, it relates to clostridial toxins, methods of inactivating these toxins and compositions (e.g., vaccines) comprising toxoids (e.g., produced by these methods). Provided are methods of producing a | 2016-02-18 |
20160045587 | Attenuated Bordetella Strains | 2016-02-18 |
20160045588 | CHLAMYDIA ANTIGEN COMPOSITIONS AND USES THEREOF - The present invention provides in part fusion proteins derived from | 2016-02-18 |
20160045589 | Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom - The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV. | 2016-02-18 |
20160045590 | ALKYLATED INFLUENZA VACCINES - The present invention provides, among other things, improved influenza vaccines based on hemagglutinins containing one or more alkylated cysteine residues. In particular, the present invention provides influenza vaccines containing hemagglutinins treated with an alkylating agent and methods of making the same. Inventive influenza vaccines provided by the present invention have a remarkable ability to retain potency as determined by Single Radial Immunodiffusion (SRID) assay upon storage. | 2016-02-18 |
20160045591 | VACCINE AND THERAPEUTIC DELIVERY SYSTEM - The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator. | 2016-02-18 |
20160045592 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION - Disclosed are yeast-based immunotherapeutic compositions, human immunodeficiency virus (HIV) antigens, and fusion proteins for the treatment and/or prevention of HIV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HIV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HIV and/or symptoms thereof. | 2016-02-18 |
20160045593 | VACCINE AGAINST BOVINE LEUKEMIA VIRUS - The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods. | 2016-02-18 |
20160045594 | DIRECTED IMMUNE STIMULATION - A synthetic polypeptide vaccine is employed for directed targeting of an individual's immune response to an antigen of interest. The synthetic polypeptide contains a carrier epitope specific for open conformers of an individual's MHC-I molecules in the presence of HLA-F, and also contains an effector epitope which elicits an immune response to the antigen of interest. The effect- or epitope may modulates an immune response to a tumor, pathogen, or autoantigen associated with an autoimmune disorder. The present vaccine exploits a role for the interaction between HLA-F and open conformers of MHC-I in the uptake of extracellular antigen for cross presentation. | 2016-02-18 |
20160045595 | Nanoparticles, Composed of Sterol and Saponin From Quillaja Saponaria Molina Process for Preparation and Use Thereof as Carrier for Amphipatic of Hydrophobic Molecules in Fields of Medicine Including Cancer Treatment and Food Related Compounds - A nanoparticle comprising at least one sterol, e.g. cholesterol and a component from | 2016-02-18 |
20160045596 | COMBINATION THERAPIES FOR TREATING HER2-POSITIVE CANCERS THAT ARE RESISTANT TO HER2-TARGETED THERAPIES - Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody. | 2016-02-18 |
20160045597 | COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1 - The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3 | 2016-02-18 |
20160045598 | Combination Treatments with Sonic Hedgehog Inhibitors - Methods for treating cancer using a combination of an inhibitor of the sonic hedgehog signaling pathway (e.g., LDE225) with radiation and a tumor antigen-specific monoclonal antibody (e.g., heat shock protein (HSP) glucose regulated protein of 94000 daltons (Grp94)-specific mAb W9, or chondroitin sulfate proteoglycan 4 (CSPG4)-targeted mAbs), or with a BRAF inhibitor, e.g., in BRAF inhibitor resistant cancers. | 2016-02-18 |
20160045599 | DEVICES, SYSTEMS AND METHODS FOR OPTOGENETIC MODULATION OF ACTION POTENTIALS IN TARGET CELLS - Aspects of the disclosure include devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering vectors to target cells. The subject systems include light-activated proteins, response proteins, nucleic acids comprising nucleotide sequences encoding these proteins, as well as expression systems that facilitate expression of these proteins in target cells. Also provided are methods of using the subject devices and systems to optogenetically inhibit and intercept action potentials in target cells, e.g., to treat a neurological or psychiatric condition in a human or non-human animal subject. | 2016-02-18 |
20160045600 | COMPOSITIONS AND METHODS FOR EFFICIENT DELIVERY OF MOLECULES TO CELLS - The present invention provides lipid aggregate compositions having at least two cationic lipids in combination with one or optionally more than one non-cationic lipids for the in vitro and/or in vivo delivery of biologically active molecules including nucleic acids, specifically DNA and RNA, and proteins into cells and tissues. Methods are also provided that use the compounds of the present invention to deliver biologically active molecules, into cells and tissues to facilitate the expression of target proteins therein. In some non-limiting embodiments, the subject lipid aggregate compositions can be used to deliver nucleic acid molecules to facilitate the expression of proteins involved in cellular reprogramming and genome editing applications. | 2016-02-18 |
20160045601 | DEPOT FORMULATIONS - Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity. | 2016-02-18 |
20160045602 | MEDICAL ORGANOGEL PROCESSES AND COMPOSITIONS - Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentation, and radiological marking. | 2016-02-18 |
20160045603 | Composition of Tiacumicin Compounds - A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided. | 2016-02-18 |
20160045604 | ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOF - The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines. | 2016-02-18 |
20160045605 | DICLOFENAC TOPICAL FORMULATION - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 2016-02-18 |
20160045606 | PARTIALLY-DENATURED PROTEIN HYDROGELS - Provided herein are partially-denatured protein (e.g., albumin) hydrogels and methods of manufacture (e.g., pH induction) and use (e.g., drug delivery) thereof. | 2016-02-18 |
20160045607 | ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE - The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides. | 2016-02-18 |
20160045608 | LONG CIRCULATING NANOPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours. | 2016-02-18 |
20160045609 | CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE - A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum. | 2016-02-18 |
20160045610 | COMPOSITIONS OF MATTER THAT REDUCE PAIN, SHOCK, AND INFLAMMATION BY BLOCKING LINOLEIC ACID METABOLITES AND USES THEREOF - A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs. | 2016-02-18 |
20160045611 | SUGAR-LINKER-DRUG CONJUGATES - The present disclosure relates to sugar-linker-drug conjugates, of the formula [A-B-]n-L-D, wherein A is a saccharide; B is a spacer, n is an integer selected from 1 to 3; L is a linker group and D is a drug having a chemically reactive functional group selected from the group consisting of a primary or secondary amine, hydroxyl, sulfhydryl, carboxyl, aldehyde and ketone. Pharmaceutical compositions comprising the conjugates and methods of using them are also provided. | 2016-02-18 |
20160045612 | FUNCTIONALIZED NANOPARTICLES FOR MEDICAL TREATMENTS - A class of functionalized nanoparticles useful in medical treatments is described. The nanoparticles have an attached carbohydrate that is selected on the basis that a cell to be treated ingests as a consequence of the presence of the carbohydrate. The nanoparticles have an attached chemical that if inside the cell is capable of treating the cell (e.g., curing a disease condition in the cell, killing the cell if it is pathogenic, or improving the health of the cell). The nanoparticle carries the chemical preferentially into the cell because the cell will ingest the carbohydrate, and thereby allows the nanoparticle and the chemical into itself. | 2016-02-18 |
20160045613 | PARTICLES HAVING PEG-YLATED SURFACES MODIFIED FOR LYMPHATIC TRAFFICKING - The subject matter disclosed herein is directed to modifying and utilizing properties of micro and/or nano-particles to traffic the particles to lymph nodes. As described herein, the properties include size, charge, and surface characteristics of the particles. | 2016-02-18 |
20160045614 | TARGETED LIPOSOMAL COMPOSITION USING ANTI-HER-2 AFFIBODY MOLECULES AND APPLICATIONS THEREOF IN CANCER TREATMENT - A liposomal composition for treatment of cancer including a PEGylated liposome loaded by an anthracycline chemotherapeutic agent, wherein the PEGylated liposome is further targeted by an effective number of affibody molecules. | 2016-02-18 |
20160045615 | CYCLODEXTRIN AND ANTIBODY-DRUG CONJUGATE FORMULATIONS - Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine anti-body-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine anti-body-drug conjugates and process drug-related impurities. | 2016-02-18 |
20160045616 | PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES - The invention provides processes for preparing a cell-binding agent chemically coupled to a drug. A first process comprises covalently attaching a linker to a cell-binding agent, an optional purification step, conjugating a drug to the cell-binding agent, a subsequent purification step, and optional holding steps. A second process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent, a subsequent purification step. holding steps, and optionally a tangential flow filtration (TFF) step. | 2016-02-18 |
20160045617 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY - The present invention provides, inter alia, methods and pharmaceutical compositions for treating or ameliorating an effect of proximal spinal muscular atrophy (SMA) and methods for preventing or slowing motor neuron death in a subject having SMA. The methods include administering to a subject in need thereof a modulator of a gene selected from the group consisting of phosphodiesterase 1c (Pde1c), Calbindin 2 (Calb2), Egl nine homolog 3 (Eg13), Metabotropic glutamate receptor 8 (mGluR8), Syn aptotagmin 1 (Syt1), CUGBP, Elav-like family member 4 (Celf4), and combinations thereof in an amount effective to treat or ameliorate an effect of SMA. Also provided are methods for preventing or slowing motor neuron death. | 2016-02-18 |
20160045618 | Methods And Compositions For Treatment Of Interferon-Resistant Tumors - The present invention provides a method for the treatment of interferon resistant bladder tumors through the use of a non-replicating agent which induces human cells to express interferon species. In particular it is noted that inducing interferon expression in the patient's body possesses properties not associated with recombinant produced, intravenously-administered interferon proteins. The present invention further provides compositions useful in the treatment of bladder cancer resistant to treatment with intravenous interferon polypeptide, by using a non-replicating agent which induces human cells to express interferon species, e.g., an antigenic, replication-deficient virus optionally carrying an interferon transgene. | 2016-02-18 |
20160045619 | METHODS OF USING OPTICAL AGENTS - In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention. | 2016-02-18 |
20160045620 | USE OF NANOMETER-SIZED PRODRUGS OF NSAIDs TO TREAT TRAUMATIC BRAIN INJURY - The present invention describes methods of delivering derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) and nanospheres thereof as well as therapeutic agents to the injured brain tissue in subjects with traumatic brain injury. The invention also provides methods of treating traumatic brain injury and related conditions. The invention further provides methods of diagnosing traumatic brain injury. | 2016-02-18 |
20160045621 | COMPLEX OF MANNOSYL SERUM ALBUMIN, METHOD OF PREPARING THE SAME, OPTICAL IMAGING PROBE AND KIT COMPRISING THE SAME - The present invention relates to a complex prepared by conjugating indocyanine green to mannosyl serum albumin in order to overcome shortcomings such as low light stability and low in vivo stability of indocyanine green that is a fluorescent dye reagent that is used during surgical operations, a preparation method thereof, an optical imaging probe comprising the same, and a kit comprising the probe. | 2016-02-18 |
20160045622 | IN VIVO CELL IMAGING - This disclosure relates to the live imaging of native intracellular proteins in eukaryotic cells, typically mammalian cells, by means of a fluorescent bead coupled to a ligand, a cell penetrating peptide and a cell export peptide adapted to interact with cell secretory proteins to remove non-bound fluorescent beads. | 2016-02-18 |
20160045623 | Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI) - The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity. | 2016-02-18 |
20160045624 | COATED PLANT VIRUS IMAGING AGENTS - An imaging nanoparticle comprising a plant virus particle having an interior surface and an exterior surface, an imaging agent that is linked to the interior and/or exterior surface, and a layer of biocompatible mineral such as silica coated over the exterior surface, is described. The imaging nanoparticle can be used in method of generating an image of a tissue region of a subject, by administering to the subject a diagnostically effective amount of an imaging nanoparticle and generating an image of the tissue region of the subject to which the imaging nanoparticle has been distributed. | 2016-02-18 |
20160045625 | [11C] AND [18F] LABELED 1,3-DIPHENYL-5-(PYRIMIDIN-2-YL)-PYRIDIN-2(1H)-ONE DERIVATIVES AND THEIR USE FOR PET IMAGING OF THE AMPA RECEPTOR - A compound selected from the group consisting of compounds represented by the formulas below or pharmaceutically acceptable salt thereof is useful in PET imaging for AMPA receptor. | 2016-02-18 |
20160045626 | Methods and Compositions for Improved Labeling of Targeting Peptides - The present application discloses compositions and methods of synthesis and use of labeled targeting peptides, such as octreotide, octreotate, or other somatostatin analogs or derivatives. The targeting peptide may be labeled with a therapeutic or diagnostic isotope, such as | 2016-02-18 |
20160045627 | SHK-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURING AND USING THE SAME - Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO:1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed. | 2016-02-18 |
20160045628 | Microwave Disinfection and Sterilization - A method and apparatus comprising microwave radiation pulses to reduce a microorganism population in an object. | 2016-02-18 |
20160045629 | Disinfectant Caps - Disinfectant caps and packaging for use with a medical device (e.g., connector, luer access device, etc.) are disclosed herein. The disinfectant caps apply the antiseptic fluid (e.g., disinfectant) directly onto the surface of the medical device. The disinfectant cap for disinfecting a surface of a medical device comprises a cap body having a bottom wall and a sidewall extending therefrom, the sidewall defining a top opening, antiseptic fluid contained within the cap body, and a deformable top wall connected to the cap body, the top wall movable from a first position sealing the antiseptic fluid within the cap body to a second position releasing the antiseptic fluid from the cap body. | 2016-02-18 |
20160045630 | STERILE STATUS INDICATOR BY MEANS OF PHASE CHANGE - A phase change material is used for the production of a sterile state indication means for a sterilization container. A sterile state indication means for a sterilization container includes a fluid-tight case containing a phase change material. In this assembly, the case wall of the case includes at least one transparent zone and an activator which can be actuated in order to release an activation energy and/or crystallization seeds. The activator is in contact with the phase change material. Further, a sterilization container includes a container trough and a container lid, including a sterile state indication means. The sterile state indication means is provided either on the container trough or on the container lid, and the activator, in the closed state of the sterilization container, is in direct or indirect connection with the respectively other element among container trough and container lid. | 2016-02-18 |
20160045631 | INK COMPOSITION FOR DETECTING HYDROGEN PEROXIDE AND INDICATOR FOR DETECTION OF HYDROGEN PEROXIDE - A primary object of the present invention is to provide a hydrogen peroxide gas detection indicator which allows more certain visual recognition of color changing according to the concentration of hydrogen peroxide gas. The structure of this invention relates to an ink composition for detecting hydrogen peroxide gas containing (1) at least one of styrene acrylic resins and styrene-maleic acid resins and (2) a methine dye. According to this invention, a color-changing layer is formed using the ink composition for detecting hydrogen peroxide gas, allowing color changing according to the concentration of hydrogen peroxide gas to be visually recognized. | 2016-02-18 |
20160045632 | METHOD AND APPARATUS FOR DISPERSING AN ACTIVE SUBSTANCE - An apparatus for dispersing an active substance has an active-substance reservoir from which active substance can be extracted and introduced into an interior space by an air stream. In order to achieve with as little expenditure as possible that the air stream has a temperature level which is optimum for extracting the active substance from the active-substance reservoir, it is proposed that the apparatus for dispersing an active substance has a mixing station, at which air streams having different temperatures are able to be mixed to the air stream so that the latter is able to be adjusted to an optimum temperature level for extracting the active substance, preferably between 19° C. and 24° C. | 2016-02-18 |
20160045633 | SYSTEMS AND METHODS FOR SURFACE DECONTAMINATION - Implementations disclosed herein provide systems and methods of automatically sterilizing a portable electronic device with ultraviolet (UV) radiation. In one implementation, the method includes distributing UV light substantially uniformly across an intended surface of a device in an enclosure, and sterilizing the intended surface using a calculated dosage of the UV light. In another implementation, an electronic device sterilization system includes an enclosure configured to selectively receive a device for sterilization using a calculated dosage of light, wherein the enclosure includes one or more LEDs, a first reflector configured to receive and reflect the light from the LEDs, and a second reflector configured to receive the light reflected from the first reflector and distribute the light uniformly onto an intended planar surface of the device. | 2016-02-18 |
20160045634 | Analgesic Formulation and Delivery Bandage - A medical dressing and analgesic formulation that is operable to provide pain relief to an injured area of the human body wherein the medical dressing is constructed so as to allow a user to create a customized size for each application of the medical dressing. The medical dressing further includes a body being planar in manner having a plurality of contiguous portions that are separated by a perforation. Each contiguous portion includes a medicament layer thereon that is operable to treat an injured are for pain. The contiguous portions in one embodiment of the medical dressing are further configured to be divisible into four quadrants wherein the user can select as few as one quadrant or more than one quadrant of each continuous portion so as to size the medical dressing to the appropriate size needed to treat the desired area of the body. | 2016-02-18 |
20160045635 | ANTI-MICROBIAL FOAMS CONTAINING POLYMER-STABILIZED SILVER NANOPARTICLES - An absorbent wound dressing comprises a hydrophilic porous substrate and polymer-stabilized silver nanoparticles distributed throughout the porous substrate. The silver nanoparticles have a particle size d | 2016-02-18 |
20160045636 | SELF-RETAINING SUTURES OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF - Absorbable monofilament fibers and self-retaining sutures with high tensile strengths have been developed. The straight pull tensile strengths of the absorbable self-retaining sutures closely approximate, equal or exceed the average minimum knot-pull tensile standards set by the United States Pharmacopeia (USP). These higher strength absorbable self-retaining sutures can therefore be used either without needing to oversize the suture for a given procedure, or by oversizing the self-retaining suture by no more than 0.1 mm in diameter. In one embodiment, the absorbable self-retaining sutures are made from poly-4-hydroxybutyrate or copolymers thereof. | 2016-02-18 |
20160045637 | COMPOSITION AND METHODS FOR ANTIMICROBIAL ARTICLES - A biocompatible controlled release form of complexed iodine is achieved by a complexation of polyvinyl alcohol based foam and characterized by a residual starch component to optimize iodine release profiles. The resulting iodine complexed polyvinyl alcohol foam may be utilized locally as an antimicrobial agent that releases controlled amounts of iodine sufficient to kill microbes for extended durations without excessive bulk and rigidity. | 2016-02-18 |
20160045638 | Thermosensitive and Crosslinkable Polymer Composite for Three-Dimensional Soft Tissue Scaffold Printing - A hydrogel material for use in three-dimensional scaffold printing is disclosed. The material is formed from a first triblock polymer having a formula ABA and a second triblock polymer having a formula AmaBAma, wherein A is a first polymer, B is a second polymer, and Ama is a methacrylate of the first polymer. The material is thermosensitive and photocrosslinkable. A method of manufacturing the material is also disclosed. | 2016-02-18 |
20160045639 | Method for Enzymatic Treatment of Tissue Products - Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix. | 2016-02-18 |
20160045640 | Allografts Combined With Tissue Derived Stem Cells for Bone Healing - There is disclosed a method of combining mesenchymal stem cells (MSCs) with a bone substrate. In an embodiment, the method includes obtaining tissue having MSCs together with unwanted cells. The tissue is digested to form a cell suspension having MSCs and unwanted cells. The cell suspension is added to the substrate. The substrate is cultured to allow the MSCs to adhere. The substrate is rinsed to remove unwanted cells. In various embodiments, the tissue is adipose tissue, muscle tissue, or bone marrow tissue. In an embodiment, there is disclosed an allograft product including a combination of MSCs with a bone substrate in which the combination is manufactured by culturing MSCs disposed on the substrate for a period of time to allow the MSCs to adhere to the substrate, and then rinsing the substrate to remove unwanted cells from the substrate. Other embodiments are also disclosed. | 2016-02-18 |
20160045641 | CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOF - The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct. | 2016-02-18 |
20160045642 | BIOENGINEERED ALLOGENEIC BLOOD VESSEL - The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases. | 2016-02-18 |
20160045643 | Method for Making Biodegradable Anti-Adhesion Membranes for Cardiac Surgery - A method for the manufacture of biodegradable membranes for preventing adhesion formation followed open heart surgery is described herein. The manufacturing of biodegradable membranes is based on polymeric composition, comprised of copolymer of polyhydroxybutyrate/hydroxyvalerate (PHBV), poly(D,L-lactide) in the ratio of the dried powders of 3:1, the resulting mixture is dissolved in chloroform to a concentration of 6-9% followed by thorough mixing for 2 hours and heating up to 35° C. The membrane is produced by electrostatic spinning (electrospinning), wherein biologically active substances from fibrinolytic agents or direct anticoagulants are embedded in the structure of the fiber. | 2016-02-18 |
20160045644 | CARBON NANOTUBE COMPOSITE AND METHOD OF MANUFACTURING THE SAME - Provided are a carbon nanotube composite containing a carbon nanotube coated with a protein having a catechol group and a metal ion bound to the catechol group and a method for manufacturing the same. According to the present disclosure, a carbon nanotube composite which exhibits controllable dispersibility and degree of crosslinkage while retaining the intrinsic physical properties of the carbon nanotube may be prepared. Since the phase change and tendency of aggregation of the carbon nanotube composite can be controlled quickly and repeatedly depending on the change in external environment, the carbon nanotube composite may be useful in various industrial fields including medicine, environment, etc. as a self-healing material. | 2016-02-18 |
20160045645 | BIODEGRADABLE POLYMER WITH ENHANCED PHYSICAL PROPERTIES INCLUDING STEREOCOMPLEX ORGANIC FILLER AND METHOD FOR PRODUCING THE SAME - Disclosed is a biodegradable polymer whose physical properties are improved by the presence of a stereocomplex organic filler. According to exemplary embodiments, the biodegradable polymer including a stereocomplex organic filler can find application in various fields, including biodegradable materials and medical materials, where conventional biodegradable polymers are difficult to use due to their inherent problems such as poor heat resistance and low strength. Also disclosed is a method for producing the biodegradable polymer. | 2016-02-18 |
20160045646 | Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders With An Implantable Medical Device - Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque. | 2016-02-18 |
20160045647 | Liquid-accommodating container for a device for providing a vacuum for medical applications, method for producing the container, and device - A liquid-accommodating container ( | 2016-02-18 |
20160045648 | System And Method For Determining A Fill Status Of A Canister Of Fluid In A Reduced Pressure Treatment System - A reduced pressure treatment system is provided that includes a canister that is fluidly connected to a tissue site and is configured to receive fluid drawn from the tissue site under the influence of a reduced pressure. A reduced pressure source provides the reduced pressure and is fluidly connected to the tissue site by a fluid communication path, which may include a source conduit, the canister, and a target conduit. A sensing device communicates with the source conduit and is configured to sense a pressure in the source conduit. A valve communicates with the source conduit and is configured to vent the reduced pressure. A processing unit communicates with the sensing device and the valve and is configured to open the valve for a selected amount of time, determine a decay of reduced pressure, and determine a fill status of the canister based on the decay of reduced pressure. | 2016-02-18 |
20160045649 | Surgical Storage Assembly - A surgical storage assembly for preventing a plurality of surgical drains from becoming impeded includes a belt that may be placed around a user. A plurality of pockets is coupled to the belt. A plurality of surgical drains is removably positioned within an associated one of the plurality of pockets. | 2016-02-18 |
20160045650 | System for Extended Storage of Red Blood Cells and Methods of Use - A system and methodology for the preservation of red blood cells is described in which red blood cells are oxygen or oxygen and carbon dioxide depleted, treated and are stored in an anaerobic environment to optimize preparation for transfusion. More particularly, a system and method for extended storage of red blood cells from collection to transfusion that optimizes red blood cells prior to transfusion is described. | 2016-02-18 |
20160045651 | ANATOMIC FIT OF A PERCUTANEOUS VAD FOR RIGHT HEART SUPPORT - An apparatus is disclosed including: a cannula having a shape closely matched to the anatomy of the right ventricle of the human heart, where the cannula has an outflow port configured to be located proximal the pulmonary artery and an inflow port located proximal the inferior vena cava. In some embodiments, the cannula is a close fit to the anatomy of at least 90%, 95%, or more of the population. | 2016-02-18 |
20160045652 | LEFT VENTRICULAR CARDIAC ASSIST PUMP AND METHODS THEREFOR - A left ventricular cardiac assist pump includes an inlet opening and a discharge opening aligned in an axial direction. The pump includes a casing spaced from a stator and impeller, with at least one connecting spacer connecting the casing and the stator. The impeller is configured to direct the blood towards the casing and the discharge opening, so that blood flows through the pump principally between the casing and the rotor-stator assembly. | 2016-02-18 |
20160045653 | PURGE-FREE MINIATURE ROTARY PUMP - Methods and systems are provided for the circulation of blood using a purge-free miniature pump. In one embodiment, a pump is provided that may comprise a housing including a rotor and a stator within a drive unit. In this embodiment, the pump may establish a primary blood flow through the space between the drive unit and the housing and a secondary blood flow between the rotor and stator. In another embodiment, a pump establishes a primary blood flow outside the housing and a secondary blood flow between the rotor and stator. In yet another embodiment, a method is provided for introducing the pump into the body and circulating blood using the pump. | 2016-02-18 |
20160045654 | Implanted Extracardiac Device for Circulatory Assistance - This invention is an implanted extracardiac device for supplementing blood circulation which comprises an implanted blood flow lumen, a blood flow increasing mechanism, and a control unit. Its design improves blood circulation when the blood flow increasing mechanism is operating, without hindering native blood flow when the mechanism is not operating. This device improves circulation without intruding on cardiac tissue or weakening the heart by completely supplanting cardiac function. Also, since the device allows native blood flow when the blood flow increasing mechanism is not in operation, it requires less power and can enable more patient mobility. | 2016-02-18 |
20160045655 | SYSTEMS AND METHODS FOR INCREASING CONVECTIVE CLEARANCE OF UNDESIRED PARTICLES IN A MICROFLUIDIC DEVICE - A microfluidic device for increasing convective clearance of particles from a fluid is provided. In some implementations, described herein the microfluidic device includes multiple layers that each define infusate, blood, and filtrate channels. Each of the channels have a pressure profile. The device can also include one or more pressure control features. The pressure control feature controls a difference between the pressure profiles along a length of the device. For example, the pressure control feature can control the difference between the pressure profile of the filtrate channel and the pressure profile of the blood channel. In some implementations, the pressure control feature controls the pressure difference between two channels such that the difference varies along the length of the channels by less than 50% of the pressure difference between the channels at the channels' inlets. | 2016-02-18 |
20160045656 | Disposable Cartridge System for Use with Sorbent or Premixed Dialysate - A hemodialysis machine defining a closed loop fluid path for dialysate solution, the fluid path comprising: a first pump chamber having a pump inlet and a pump outlet, a dialyser having a dialyser inlet and a dialyser outlet, a conduit connected between the outlet of the first pump chamber and the inlet of the dialyser, a second pump chamber having a pump inlet and a pump outlet, a conduit connected between the outlet of the dialyser and the inlet of the second pump chamber, a dialysate regeneration device having a filter inlet and a filter outlet, a conduit connected between the outlet of the second pump chamber and the inlet of the dialysate regeneration device, a reservoir having a reservoir inlet and a reservoir outlet, a conduit connected between the outlet of the dialysate regeneration device and the inlet of the reservoir and, a conduit connected between the outlet of the reservoir and the inlet of the first pump chamber. | 2016-02-18 |
20160045657 | METHOD OF ADJUSTING BLOOD FLOW IN A DIALYSIS MACHINE AND DIALYSIS MACHINE - Methods for the adjustment of a blood flow in a blood treatment machine/dialysis machine are disclosed. Steps for achieving a blood flow having an optimum value include determining a blood flow target value, altering the blood flow at a predetermined blood flow alteration rate, comparing a venous pressure with a venous pressure threshold, an arterial pressure with an arterial pressure threshold, and the blood flow with the blood flow target value, determining if a dialysis fluid parameter extreme is reached, storing an optimum blood flow value, in dependence on a blood flow (according to a value which is stored in a data table and which takes into account the blood flow target value as well as the measurement lag) in an optimum blood flow value memory, for which the dialysis fluid parameter threshold, the venous pressure threshold or the arterial pressure threshold, or the blood flow target value has been reached. | 2016-02-18 |